BITT-ID is developing a platform for treating infectious disease through a novel immunotherapy. Chronic infections, as well as some acute infections, can become disguised once inside the host, inducing suppression of the host response through regulatory T cells (Tregs). BITT has developed an approach to infectious disease that targets the host Tregs, not the microorganism, through tumor necrosis factor receptor 2 (TNFR2) antagonism. This platform approach has two advantages:
- No antibiotic resistance
- One platform for all infections
BITT-ID has built a broad portfolio of intellectual property around targeting TNFR2 in infectious disease and has identified lead monoclonal antibody c and idates. We are currently exploring treatment models in human and animal health. BITT-ID’s technology was developed at Massachusetts General Hospital and Harvard Medical School.
To download a complete overview of our infectious disease platform click here.